Corbus Pharmaceuticals (NASDAQ: CRBP)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Corbus Pharmaceuticals Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Corbus Pharmaceuticals Company Info
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.
News & Analysis
You might want to avoid buying it, though.
A late-stage clinical failure is weighing heavily on the biotech's stock today.
These cheap companies have upcoming binary catalysts for explosive growth.
Pharmaceutical stocks are popular with Robinhood Investors, including three I would stay away from and one that I wouldn't.
Could the most popular biotech stocks on Robinhood be the biggest winners for other investors?
These have the highest analyst ratings among Robinhood's 100 most popular stocks.
These pharmaceutical giants are already preparing for the possibility of medical marijuana legalization.
Two biotechs have big risks, one is a buy, and the other is a big opportunity to consider.
CRBP earnings call for the period ending December 31, 2020.
CRBP earnings call for the period ending September 30, 2020.
CRBP earnings call for the period ending June 30, 2020.
CRBP earnings call for the period ending March 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.